Objective: To investigate the expression of COX-2 in and benign prostatic hyperplasia and prostate cancer and its clinical implications.
Methods: Forty-two patients with and benign prostatic hyperplasia and 16 with prostate cancer were studied by immunohischemistry and western blot.
Results: Immunohischemiscal study showed positive results in 15 of the 16 patients and 11 of the 42 patients. Western blot showed that the expression of COX-2 was higher in prostate cancer than in and benign prostatic hyperplasia tissues(P < 0.01).
Conclusion: Overexpression of COX-2 in prostate cancer may be related to the staging of prostate cancer.